562 related articles for article (PubMed ID: 23878072)
1. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
[TBL] [Abstract][Full Text] [Related]
2. p53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour.
Yang Y; Zhen T; Zhang F; Dai S; Kang L; Liang Y; Xue L; Han A
J Clin Pathol; 2014 Mar; 67(3):235-42. PubMed ID: 24072730
[TBL] [Abstract][Full Text] [Related]
3. Positive feedback loop of hepatoma-derived growth factor and β-catenin promotes carcinogenesis of colorectal cancer.
Lian J; Tang J; Shi H; Li H; Zhen T; Xie W; Zhang F; Yang Y; Han A
Oncotarget; 2015 Oct; 6(30):29357-74. PubMed ID: 26296979
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
6. Interactomic approach for evaluating nucleophosmin-binding proteins as biomarkers for Ewing's sarcoma.
Haga A; Ogawara Y; Kubota D; Kitabayashi I; Murakami Y; Kondo T
Electrophoresis; 2013 Jun; 34(11):1670-8. PubMed ID: 23483572
[TBL] [Abstract][Full Text] [Related]
7. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
8. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Oncogene; 2000 Aug; 19(37):4298-301. PubMed ID: 10980604
[TBL] [Abstract][Full Text] [Related]
9. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
10. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
[TBL] [Abstract][Full Text] [Related]
11. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer.
Lin YW; Li CF; Chen HY; Yen CY; Lin LC; Huang CC; Huang HY; Wu PC; Chen CH; Chen SC; Tai MH
Oral Oncol; 2012 Jul; 48(7):629-35. PubMed ID: 22361040
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma.
Shih TC; Tien YJ; Wen CJ; Yeh TS; Yu MC; Huang CH; Lee YS; Yen TC; Hsieh SY
J Hepatol; 2012 Sep; 57(3):584-91. PubMed ID: 22613005
[TBL] [Abstract][Full Text] [Related]
13. Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics.
Kikuta K; Tochigi N; Shimoda T; Yabe H; Morioka H; Toyama Y; Hosono A; Beppu Y; Kawai A; Hirohashi S; Kondo T
Clin Cancer Res; 2009 Apr; 15(8):2885-94. PubMed ID: 19351769
[TBL] [Abstract][Full Text] [Related]
14. Ewing's sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone.
Margulies BS; DeBoyace SD; Damron TA; Allen MJ
Bone; 2015 Oct; 79():121-30. PubMed ID: 26051470
[TBL] [Abstract][Full Text] [Related]
15. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.
Nakatani F; Ferracin M; Manara MC; Ventura S; Del Monaco V; Ferrari S; Alberghini M; Grilli A; Knuutila S; Schaefer KL; Mattia G; Negrini M; Picci P; Serra M; Scotlandi K
J Pathol; 2012 Apr; 226(5):796-805. PubMed ID: 21960059
[TBL] [Abstract][Full Text] [Related]
16. BLCAP induces apoptosis in human Ewing's sarcoma cells.
Fan DG; Zhao F; Ding Y; Wu MM; Fan QY; Shimizu K; Dohjima T; Nozawa S; Wakahara K; Ohno T; Guo YS; Ma BA; Jiang JL
Exp Biol Med (Maywood); 2011 Sep; 236(9):1030-5. PubMed ID: 21844121
[TBL] [Abstract][Full Text] [Related]
17. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
18. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.
Lu Q; Lu M; Li D; Zhang S
Mol Med Rep; 2018 Oct; 18(4):3577-3588. PubMed ID: 30106161
[TBL] [Abstract][Full Text] [Related]
20. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
